个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Activation of the PI3K-AKT signaling pathway by SPARC contributes to the malignant phenotype of cholangiocarcinoma cells.

| 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Deng Shikang[1,2] * ; Zhang Li[2] ; Li Jiao[2] ; Jin Yan[2] ; Wang Junfeng[2,*1] ;
机构： [1]Medical School, Kunming University of Science and Technology, Kumming, Yunnan, China [2]Department of Hepatobiliary and Pancreatic Surgery, The First People’s Hospital of Yunnan Province, Affiliated Hospital of Kunming University of Science and Technology, Kumming, Yunnan, China
出处：
DOI： 10.1016/j.tice.2022.101756
ISSN：

摘要：
Cholangiocarcinoma (CCA) is a primary biliary epithelium malignancy with limited therapies, poor prognosis and high mortality rate. Nowadays, the molecular mechanisms of CCA remain elusive. SPARC has been proposed to be highly expressed in clinical CCA tissues, but few studies has been elucidated its functions in CCA. In the current study, we aimed to investigate the functional role of SPARC in the progression of CCA. In this study, a significantly increased expression of SPARC was observed in CCA tissues and cells. Knockdown of SPARC by RNA interference significantly impeded the proliferation of CCA cells. Moreover, SPARC silencing hampered the migration and invasion of CCA cells by inhibiting EMT. In parallel, overexpression of SPARC in RBE cells had the opposite effects. Mechanically, SPARC promoted proliferation, migration, invasion, and EMT of CCA cells in vitro via activating the PI3K-AKT signaling. Overall, our integrated analysis revealed that SPARC plays a crucial role in CCA progression via the PI3K-AKT signaling pathway, which suggests that targeting SPARC might represent a promising approach for improving CCA patient's clinical outcome.Copyright © 2022 Elsevier Ltd. All rights reserved.

基金：
This research was supported by the Yunnan Provincial High-Level Medical Technical Talents Training Project (H-2019038), Joint project of Yunnan Provincial Department of science and technology and Kunming Medical University on applied basic research (202101AY070001-233), Scientific Researching Fund of First People’s Hospital of Yunnan Province (KHBS-2020-019), Yunnan Provincial High-level Medical Technical Talents Training Project (L-2019016), Recruited Talent Program of Kunming University of Science and Technology (KKSY201660007).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 4 区 生物学
小类 | 4 区 解剖学与形态学 4 区 细胞生物学
最新[2023]版：
大类 | 4 区 生物学
小类 | 3 区 解剖学与形态学 4 区 细胞生物学
JCR分区：
出版当年[2021]版：
Q2 ANATOMY & MORPHOLOGY Q4 CELL BIOLOGY
最新[2023]版：
Q1 ANATOMY & MORPHOLOGY Q3 CELL BIOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者机构： [1]Medical School, Kunming University of Science and Technology, Kumming, Yunnan, China [2]Department of Hepatobiliary and Pancreatic Surgery, The First People’s Hospital of Yunnan Province, Affiliated Hospital of Kunming University of Science and Technology, Kumming, Yunnan, China
通讯作者：
通讯机构： [2]Department of Hepatobiliary and Pancreatic Surgery, The First People’s Hospital of Yunnan Province, Affiliated Hospital of Kunming University of Science and Technology, Kumming, Yunnan, China [*1]Department of Hepatobiliary and Pancreatic Surgery, Yunnan First People’s Hospital, Affiliated Hospital of Kunming University of Science and Technology, No. 157, Jinbi Road, Kunming, Yunnan, 650032, China.
推荐引用方式(GB/T 7714)：
Deng Shikang,Zhang Li,Li Jiao,et al.Activation of the PI3K-AKT signaling pathway by SPARC contributes to the malignant phenotype of cholangiocarcinoma cells.[J].TISSUE & CELL.2022,76:doi:10.1016/j.tice.2022.101756.
APA：
Deng Shikang,Zhang Li,Li Jiao,Jin Yan&Wang Junfeng.(2022).Activation of the PI3K-AKT signaling pathway by SPARC contributes to the malignant phenotype of cholangiocarcinoma cells..TISSUE & CELL,76,
MLA：
Deng Shikang,et al."Activation of the PI3K-AKT signaling pathway by SPARC contributes to the malignant phenotype of cholangiocarcinoma cells.".TISSUE & CELL 76.(2022)

资源点击量：82325 今日访问量：0 总访问量：681 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 云南省第一人民医院 技术支持：重庆聚合科技有限公司 地址：云南省昆明市西山区金碧路157号